会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • NANOPARTICLES
    • 纳米粒子
    • WO2016198862A1
    • 2016-12-15
    • PCT/GB2016/051693
    • 2016-06-08
    • KING'S COLLEGE LONDON
    • THANOU, MariaWRIGHT, Michael James LeeCENTELLES, MiguelMILLER, Andrew DavidGEDROYC, Wladyslaw
    • A61K9/127A61K49/08A61K49/10A61K49/18A61K31/4745A61K31/704
    • A61K9/1272A61K31/4745A61K31/704A61K41/0052A61K49/085A61K49/106A61K49/1812A61K49/1839
    • The invention provides a (drug-containing) lipid nanoparticle with: (i) at least one phospholipid; (ii) at least one lysolipid; and (iii) at least one phospholipid comprising a hydrophilic polymer;and (iv) at least one structural lipid of formula (I) which has the following general structure: (I) wherein R and R' are long hydrocarbyl hydrophobic chains, Y is a linker element, and PHG is a polar head group described as large according to its van der Waals radius, and which is different from the phospholipid (i). The lipid nanoparticle can release a drug (or API) from within the lipid nanoparticleas a result of focussed ultrasound (FUS) applied continuously, at least twice, to a desired part of the body to induce hyperthermia (an increase in temperature). FUS is applied after the lipid nanoparticle containing the drug has been administered to the live subject, and causes controlled release of the drug at the desired site of the body. Ultrasound is then halted, and the site of interest allowed to cool. Ultrasound is then applied again. Lipidnanoparticles can be labelled (for MRI, NIRF imaging),enablin greal time monitoring of the drug in the human body. Imaging information can be used to direct and guide the nature of the FUS applied to the site of interest.
    • 本发明提供了一种(含药物)脂质纳米颗粒,其具有:(i)至少一种磷脂; (ii)至少一种溶脂剂; 至少一种包含亲水性聚合物的磷脂;和(iv)至少一种具有以下一般结构的式(I)结构脂质:(I)其中R和R'是长烃基疏水链,Y是 连接体元件,PHG是根据其范德华半径描述为大的极性头基,并且与磷脂(i)不同。 脂质纳米颗粒可以从脂质纳米颗粒内释放药物(或API),这是聚焦超声(FUS)连续施用至少两次到身体所需部位以诱发高热(温度升高)的结果。 在含有药物的脂质纳米颗粒已经施用于活体受试者之后施用FUS,并且导致药物在体内所需位点的受控释放。 然后停止超声波,感兴趣的部位允许冷却。 然后再次应用超声波。 脂质体纳米颗粒可以被标记(用于MRI,NIRF成像),对人体中药物的安定时间进行时间监测。 成像信息可用于指导和指导应用于感兴趣的站点的FUS的性质。
    • 3. 发明申请
    • PRECISION THERAPEUTICS
    • 精密治疗
    • WO2016198859A1
    • 2016-12-15
    • PCT/GB2016/051690
    • 2016-06-08
    • GLOBALACORN LTD.KING'S COLLEGE LONDON
    • THANOU, MariaWRIGHT, Michael James LeeCENTELLES, MiguelMILLER, Andrew DavidGEDROYC, WladyslawSPENCE, Paul
    • A61K41/00A61K49/18A61K47/48A61K9/127A61P35/00
    • A61K49/1812A61K9/0007A61K9/127A61K41/0028A61K41/0052A61K47/6911
    • The invention provides a pharmaceutical composition comprising (a combination of): - imaging lipid nanoparticles (imaging LNPs); and - one or more therapeutic agent(s). The one or more therapeutic agent(s) may be separate from said imaging LNPs, and/or entrapped within said imaging LNPs to form theranostic nanoparticles (TNPs). Imaging LNPs (or TNPs) may have receptor-targeting ligands. Post administration, when sufficient imaging LNPs (or TNPs) reach target sites such as cancerous lesions, then targets may become identified using clinically relevant imaging modalities such as MRI. Image-guided hyperthermia (IgFHT) applied to target sites enables imaging LNPs (or TNPs) still in the blood pool, along with (additional) therapeutic agent(s), to partition substantially into target tissues for therapy by means of hyperpermeability and retention (HPR). Confirmation of therapeutic outcomes can be followed by clinically relevant imaging modalities such as MRI.
    • 本发明提供了一种药物组合物,其包含(组合):成像脂质纳米颗粒(成像LNPs); 和 - 一种或多种治疗剂。 所述一种或多种治疗剂可以与所述成像LNP分离,和/或包埋在所述成像LNPs内以形成纳米颗粒(TNPs)。 成像LNPs(或TNP)可能具有受体靶向配体。 后行管理,当足够的成像LNP(或TNP)到达目标部位如癌性病变时,则可以使用临床相关的成像方式(例如MRI)鉴定目标。 应用于靶位点的图像引导热疗(IgFHT)使得仍然在血液池中的LNP(或TNP)与(附加的)治疗剂一起成像以通过高渗透性和保留性将其基本分配到靶组织进行治疗 HPR)。 治疗结果的确认可以跟随临床相关的成像方式,如MRI。